About Romosozumab
            
            Class: | Monoclonal antibody (sclerostin inhibitor)  
Use: | Treatment of osteoporosis in postmenopausal women at high risk for fracture  
Adult dose: | 210 mg (administered as 105 mg subcutaneously once a month for 12 months)  
Pediatric dose: | Not established; not indicated for use in pediatric patients  
Side effects: | Headache, injection site reactions, musculoskeletal pain, hypocalcemia, and increased risk of cardiovascular events  
Contraindications: | Hypocalcemia, history of myocardial
         
        
            
                
                
                    
                        Drug Class
                    
                    Monoclonal antibody (sclerostin inhibitor)
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of osteoporosis in postmenopausal women at high risk for fracture
                 
                
                
                    
                        Storage Requirements
                    
                    Store in the refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze; may be kept at room temperature (up to 25°C or 77°F) for up to 30 days before use
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: Amgen Inc., U.S.A
                    
                    
                    Package Size
                    Prefilled Syringe x 2
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 2484.00
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        210 mg (administered as 105 mg subcutaneously once a month for 12 months)
                    
                    
                        Pediatric Dose
                    
                    
                        Not established; not indicated for use in pediatric patients
                    
                 
                
                
                    
                        Side Effects
                    
                    Headache, injection site reactions, musculoskeletal pain, hypocalcemia, and increased risk of cardiovascular events
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypocalcemia, history of myocardial infarction or stroke within the past year, and hypersensitivity to romosozumab or any component of the formulation
         
        
        
            
                Important Warnings
            
            Risk of serious cardiovascular events; monitor for signs and symptoms of hypocalcemia; not recommended for patients with a history of cardiovascular disease; ensure adequate calcium and vitamin D intake during treatment
         
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.